|
Preclinical Study Presented at the International Congress of
Endocrinology Shows Intravail(R) Drug Delivery Technology Provides
Unmatched Non-Invasive Delivery of an Anti-Obesity Peptide
SAN DIEGO, CA, Nov 12, 2008 (MARKET WIRE via COMTEX) --
Aegis Therapeutics LLC announced today that preclinical data was
presented at the 2008 International Congress of Endocrinology in Rio
de Janeiro, Brasil demonstrating that its Intravail(R) formulation
technology provides unmatched non-invasive delivery of the OB-3
peptide, a peptide previously shown to control weight gain and
glucose levels in an animal model of diabetes.
The results of the study, presented by Dr. Patricia Grasso, Associate
Professor in the Department of Medicine and Center for Cell Biology
and Cancer Research, Albany Medical College, Albany, NY, examined the
uptake profile, serum half-life, and relative bioavailability of
[D-Leu-4] OB3 in male Swiss Webster mice comparing peptide delivery
by the intranasal and three separate injection routes. Intranasal
delivery using the homogeneous aqueous Intravail(R) excipient
formulation provided higher bioavailability than that achieved using
intraperitoneal, subcutaneous, or intramuscular injection.
The authors concluded that intranasal delivery of this peptide may
have potential as a novel, convenient, and non-invasive approach to
the treatment of obesity and its associated metabolic dysfunctions in
humans.
The complete citation of this study is: "Uptake Of Mouse [D-Leu-4]
OB3, A Synthetic Peptide Amide With Leptin-Like Activity, In Male
Swiss Webster Mice; A Pharmacokinetic Study Comparing
Intraperitoneal, Subcutaneous, Intramuscular, And Intranasal Delivery
Systems." Author(s): Novakovic ZM; Leinung MC; Lee DW; Grasso P; ICE
2008 -- International Congress of Endocrinology Nov. 08-12, 2008 -
Rio de Janeiro - Brasil (Abstract No. 00198).
About Aegis Therapeutics
Aegis Therapeutics LLC is a drug delivery technology company
commercializing its patented or proprietary drug delivery and drug
formulation technologies through product-specific licenses. Our
Intravail(R) drug delivery technology enables the non-invasive
delivery of a broad range of protein, peptide and non-peptide
macromolecular therapeutics that can currently only be administered by
injection. Aegis' Intravail(R) absorption enhancement agents provide
exceptionally high and unmatched bioavailability performance,
comparable in efficiency to subcutaneous injection, via the
intranasal administration route. Intravail(R) has also been
successfully applied to buccal, oral, and rectal administration of
both small molecule and peptidic drugs. Our ProTek(R) technology
allows creation of proprietary, easily manufacturable, and stable
aqueous or lyophilized dosage forms that maintain the integrity and
physiological activity of many protein and peptide therapeutics.
ProTek(R) technology is applicable to injectable, intranasal, and
other dosage forms of peptide or protein therapeutics.
For more information about Aegis, please visit the Aegis website:
http://www.aegisthera.com.
Contact:
Ralph Barry
Chief Business Officer
Aegis Therapeutics LLC
1-858-618-1400 Ext. 102
Email: Email Contact
SOURCE: Aegis Therapeutics LLC
http://www2.marketwire.com/mw/emailprcntct?id=5CC96EF05E10E5B3
[ Back To TMCnet.com's Homepage ]
|
INDUSTRIES
Activate Email 
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO East, January 20-22, 2010. Miami, FL.
